Abstract
In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.
Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease
Current Vascular Pharmacology
Title: What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document
Volume: 8 Issue: 6
Author(s): Giuseppe Mancia and Guido Grassi
Affiliation:
Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease
Abstract: In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.
Export Options
About this article
Cite this article as:
Mancia Giuseppe and Grassi Guido, What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563942
DOI https://dx.doi.org/10.2174/157016110793563942 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanism and Anticancer Activity of the Metabolites of an Endophytic Fungi from Eucommia ulmoides Oliv
Anti-Cancer Agents in Medicinal Chemistry General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Actual Knowledge of Systemic Inflammation Reaction During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Vascular Risk Factors and Lesions of Vascular Nature in Magnetic Resonance as Predictors of Progression to Dementia in Patients with Mild Cognitive Impairment
Current Alzheimer Research Socioeconomic Position and Type 2 Diabetes Mellitus in Europe 1999- 2009: a Panorama of Inequalities
Current Diabetes Reviews Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research Prothrombotic Potential of NSAID in Ischemic Heart Diesase
Mini-Reviews in Medicinal Chemistry Therapeutic Perspectives of Food Bioactive Peptides: A Mini Review
Protein & Peptide Letters Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology Recent Trends on the Use of Nanoparticles for Nitric Oxide Delivery in Antimicrobial Applications
Drug Delivery Letters Role of NLRP-3 Inflammasome in Hypertension: A Potential Therapeutic Target
Current Pharmaceutical Biotechnology The Coronary Circulation in Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Tenofovir-Related Nephropathies in HIV-Infected Patients
Current Vascular Pharmacology Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations
Current Clinical Pharmacology Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design Sympathetic Nervous System, Genes and Human Essential Hypertension
Current Neurovascular Research Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy